Register
Community
Overview
Experts
Editors
Fellows
Code of conduct
Company
About Us
FAQs
Privacy Policy
Terms of Use
Careers
Programs
News
News Releases
Press Coverage
Publications
Blog
Contact Us
Sign in
Please select the option that best describes you:
Topics:
Biologics
•
Pulmonology
•
Bronchiectasis
Do you use biologic agents in patients with eosinophilic bronchiectasis?
If so, what is your threshold to start?
Related Questions
What is your approach to the work up and evaluation of loss of asthma control while on a biologic such as dupilumab?
Is there a role for biologics to improve lung function in patients who have severe asthma with daily symptoms and reduced lung function but do not experience frequent exacerbations?
Do you use or recommend clinical severity scores or other parameters in helping prognostication in patients with refractory status epilepticus?
What is your approach to withdrawal of ventilatory support at the end of life?
Do you treat non-albicans strains of Candida on sputum culture or BAL in patients who are immunosuppressed?
What would be your second pressor of choice if patients with LVOT obstruction remain persistently hypotensive on phenylephrine?
Does your institution have formal policies or work flows to reduce unnecessary IGRAs ordered for patients on biologics?
What are your top takeaways from CHEST 2024?
Do you routinely consider evaluation for EDAC in patients with asthma or COPD on maximal inhaler therapy who have refractory symptoms?
How small of a nodule would you attempt to biopsy with robotic bronchoscopy?
